bluebird bio, Inc. – LSE:0HOH.L
bluebird bio stock price today
bluebird bio stock price monthly change
bluebird bio stock price quarterly change
bluebird bio stock price yearly change
bluebird bio key metrics
Market Cap | 81.71M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.62 |
Revenue | 21.72M |
EBITDA | -228.11M |
Income | -78.36M |
Revenue Q/Q | 17353.52% |
Revenue Y/Y | 322.58% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1050.01% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freebluebird bio stock price history
bluebird bio stock forecast
bluebird bio financial statements
| Dec 2022 | 62K | 32.23M | 51987.1% |
|---|---|---|---|
| Mar 2023 | 2.38M | 34.04M | 1429.78% |
| Jun 2023 | 6.89M | -72.90M | -1058.17% |
| Sep 2023 | 12.39M | -71.73M | -578.85% |
| Sep 2025 | 84.91M | -16.63M | -19.59% |
|---|---|---|---|
| Dec 2025 | 99.26M | -9.81M | -9.89% |
| Mar 2026 | 93.42M | -23.48M | -25.14% |
| Jun 2026 | 108.90M | -18.08M | -16.6% |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 554902000 | 358.55M | 64.62% |
|---|---|---|---|
| Mar 2023 | 692736000 | 337.99M | 48.79% |
| Jun 2023 | 663393000 | 374.37M | 56.43% |
| Sep 2023 | 613608000 | 391.07M | 63.73% |
| Dec 2022 | -56.27M | 103.24M | -115K |
|---|---|---|---|
| Mar 2023 | -86.63M | 82.13M | 130.45M |
| Jun 2023 | -72.72M | 6.94M | -445K |
| Sep 2023 | -61.84M | 62.08M | -42K |
bluebird bio alternative data
| Aug 2023 | 323 |
|---|---|
| Sep 2023 | 323 |
| Oct 2023 | 323 |
| Nov 2023 | 323 |
| Dec 2023 | 323 |
| Jan 2024 | 323 |
| Feb 2024 | 323 |
| Mar 2024 | 323 |
| Apr 2024 | 323 |
| May 2024 | 323 |
| Jun 2024 | 323 |
| Jul 2024 | 323 |
bluebird bio other data
| Patent |
|---|
Grant Filling date: 10 Feb 2017 Issue date: 10 May 2022 |
Grant Filling date: 29 Mar 2018 Issue date: 1 Mar 2022 |
Application Filling date: 13 Dec 2019 Issue date: 3 Feb 2022 |
Application Filling date: 6 Nov 2019 Issue date: 6 Jan 2022 |
Application Filling date: 14 Jun 2019 Issue date: 26 Aug 2021 |
Application Filling date: 12 Apr 2019 Issue date: 19 Aug 2021 |
Application Filling date: 26 Apr 2019 Issue date: 29 Jul 2021 |
Application Filling date: 15 Jan 2021 Issue date: 15 Jul 2021 |
Application Filling date: 15 Jan 2021 Issue date: 15 Jul 2021 |
Application Filling date: 17 Dec 2020 Issue date: 10 Jun 2021 |
| Insider | Compensation |
|---|---|
| Mr. Nick Leschly (1973) Pres, Chief Executive Officer & Director | $1,090,000 |
| Mr. William D. Baird III (1972) Chief Financial Officer | $808,890 |
Dr. David M. Davidson (1964) Chief Medical Officer | $705,000 |
| Dr. Philip D. Gregory (1971) Chief Scientific Officer | $660,800 |
Mr. Jason F. Cole (1973) Chief Operating & Legal Officer and Sec. | $619,800 |
Ms. Kathleen A. Wilkinson Chief People Officer | |
Ms. Ingrid Goldberg Vice President of Investor Relations | |
| Ms. Katy Burnett Interim Principal Accounting Officer, Senior Director & Global Controller | |
Ms. Elizabeth Pingpank Director of Corporation Communications | |
Dr. Derek Adams Ph.D. Chief Technology & Manufacturing Officer |
-
What's the price of bluebird bio stock today?
One share of bluebird bio stock can currently be purchased for approximately $181.25.
-
When is bluebird bio's next earnings date?
Unfortunately, bluebird bio's (0HOH.L) next earnings date is currently unknown.
-
Does bluebird bio pay dividends?
No, bluebird bio does not pay dividends.
-
How much money does bluebird bio make?
bluebird bio has a market capitalization of 81.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 720.04% to 29.5M US dollars.
-
What is bluebird bio's stock symbol?
bluebird bio, Inc. is traded on the LSE under the ticker symbol "0HOH.L".
-
What is bluebird bio's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of bluebird bio?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are bluebird bio's key executives?
bluebird bio's management team includes the following people:
- Mr. Nick Leschly Pres, Chief Executive Officer & Director(age: 52, pay: $1,090,000)
- Mr. William D. Baird III Chief Financial Officer(age: 53, pay: $808,890)
- Dr. David M. Davidson Chief Medical Officer(age: 61, pay: $705,000)
- Dr. Philip D. Gregory Chief Scientific Officer(age: 54, pay: $660,800)
- Mr. Jason F. Cole Chief Operating & Legal Officer and Sec.(age: 52, pay: $619,800)
- Ms. Kathleen A. Wilkinson Chief People Officer
- Ms. Ingrid Goldberg Vice President of Investor Relations
- Ms. Katy Burnett Interim Principal Accounting Officer, Senior Director & Global Controller
- Ms. Elizabeth Pingpank Director of Corporation Communications
- Dr. Derek Adams Ph.D. Chief Technology & Manufacturing Officer
-
How many employees does bluebird bio have?
As Jul 2024, bluebird bio employs 323 workers.
-
When bluebird bio went public?
bluebird bio, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is bluebird bio's official website?
The official website for bluebird bio is bluebirdbio.com.
-
Where are bluebird bio's headquarters?
bluebird bio is headquartered at 60 Binney Street, Cambridge, MA.
-
How can i contact bluebird bio?
bluebird bio's mailing address is 60 Binney Street, Cambridge, MA and company can be reached via phone at +33 94999300.
bluebird bio company profile:
bluebird bio, Inc.
bluebirdbio.comLSE
375
Medical - Pharmaceuticals
Healthcare
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
:
ISIN: US09609G1004
:
